Sisram Medical Ltd (HKG:1696)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 1.41B |
| Revenue (ttm) | 2.84B |
| Net Income (ttm) | 148.01M |
| Shares Out | 468.34M |
| EPS (ttm) | 0.32 |
| PE Ratio | 9.56 |
| Forward PE | 6.22 |
| Dividend | 0.10 (3.15%) |
| Ex-Dividend Date | Aug 26, 2025 |
| Volume | 365,600 |
| Average Volume | 519,675 |
| Open | 3.140 |
| Previous Close | 3.020 |
| Day's Range | 2.980 - 3.140 |
| 52-Week Range | 2.960 - 8.070 |
| Beta | 1.18 |
| RSI | 35.55 |
| Earnings Date | Mar 23, 2026 |
About Sisram Medical
Sisram Medical Ltd engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home use devices, injectables, and cosmeceuticals products in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio for various wellness businesses, including hair growth and removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue... [Read more]
Financial Performance
In 2025, Sisram Medical's revenue was $365.35 million, an increase of 4.65% compared to the previous year's $349.11 million. Earnings were $19.02 million, a decrease of -24.32%.
Financial numbers in USD Financial StatementsNews
Geographic diversification is key to resilience, says Israel-based Sisram Medical
Lior Dayan of Hong Kong-listed Israeli firm Sisram Medical discusses the company’s 2025 earnings. He adds that Sisram’s expansion into direct operations across Asia Pacific has strengthened its resili...
Sisram Medical Earnings Call Transcript: H2 2025
Revenue grew 4.7% to $365M in 2025, led by APAC and injectables, while North America declined. Gross margin fell to 58.9% due to tariffs and mix, but adjusted net profit rose 7.9%. Strategic focus remains on expanding the ecosystem and AI, with strong growth expected in APAC.
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising results from initial commercialization in China, with exp...
Sisram Medical to Announce 2025 Annual Results on Monday, March 23, 2026
Earnings Conference Call to be Held on March 24, 2026 HONG KONG, March 12, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively refe...
Alma, a Sisram Medical Company, Advances the Future of Intelligent Aesthetics at IMCAS World Congress 2026
New clinical evidence highlights a smarter, technology-driven approach to scar management, rejuvenation, and tattoo removal HONG KONG, Feb. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or...
Sisram Medical Partners with Sinmait Medical Technology to Build Next-Generation Manufacturing and Innovation Hub in China
HONG KONG, Jan. 21, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offeri...
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; tog...
Sisram Medical Launches Universkin by Alma in Hong Kong, Pioneering a New Era of AI-assisted Personalized Skincare
HONG KONG , Nov. 21, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...
Half Year 2025 Sisram Medical Ltd Earnings Call Transcript
Half Year 2025 Sisram Medical Ltd Earnings Call Transcript
Sisram Medical Delivers Strong Third-Quarter 2025 Performance with Robust Momentum Across Key Markets and Core Businesses
HONG KONG , Oct. 28, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness gr...
Sisram Medical Earnings Call Transcript: H1 2025
Revenue for H1 2025 declined 1.9% to $165.5 million, with strong growth in Asia-Pacific offsetting North American weakness. Injectables revenue surged 218%, and new launches like Daxxify and Universe Skin are expected to drive H2 growth.
Sisram Medical Earnings Call Transcript: H2 2024
Revenue declined 2.8% to $349.1M in 2024, but gross margin improved to 62.1% and direct sales rose to 87% of revenue. New launches and injectables commercialization in China are expected to drive growth in 2025, despite ongoing macroeconomic and regional risks.
Sirsram Medical announces NMPA approval for DAXXIFY®
Marking the introduction of the world's first and only peptide-powered botulinum toxin product to Mainland China HONG KONG , Sept. 9, 2024 /PRNewswire/ -- Sisram Medical (1696.HK), a global leading in...
Sisram Medical Earnings Call Transcript: H1 2024
Revenue for H1 2024 declined 1.7% year-over-year to $168.7 million, with gross margin rising to 62.4%. Growth in Asia Pacific, Europe, and Middle East & Africa offset North American weakness, while new product launches and expanded direct sales are expected to drive H2 momentum.